Amylyx price target raised to $12 from $8 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Amylyx (AMLX) to $12 from $8 and keeps a Buy rating on the shares. Avexitide was well tolerated with few side effects and without a clinically relevant increase of percentage time with glucose greater than 250 mg/dL, the analyst tells investors in a research note. The firm thinks these are promising data and believes avexitide might have a direct impact on future post bariatric hypoglycemia treatment strategy.